Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4MS | ISIN: BMG762791017 | Ticker-Symbol: 87S
Tradegate
24.04.25
09:04 Uhr
9,304 Euro
-0,174
-1,84 %
1-Jahres-Chart
ROIVANT SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
ROIVANT SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
9,5349,63818:36
9,5349,63618:36

Aktuelle News zur ROIVANT SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiRoivant Sciences stock holds $18 target, management shuffle3
MoCantor Fitzgerald maintains overweight on Roivant Sciences stock1
MoImmunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift2
MoImmunovant narrows R&D focus as Roivant execs take CEO, CFO posts1
MoRoivant Sciences Ltd. - 8-K, Current Report1
MoImmunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402150Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO...
► Artikel lesen
ROIVANT SCIENCES Aktie jetzt für 0€ handeln
MoRoivant Sciences: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-14021
10.04.Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In2
19.03.Roivant, Immunovant Succeed In Phase 3. But There's A Twist - And Shares Tumbled.7
19.03.Roivant: Immunovant Reports Positive Results From MG And CIDP Studies; Stocks Down In Pre-market2
19.03.Immunovant, Roivant slip after trial data for autoimmune disorder therapy2
19.03.Roivant Sciences Ltd. - 8-K, Current Report2
19.03.Roivant Sciences: Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies172Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a...
► Artikel lesen
18.03.Roivant Sciences: Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs2
07.03.Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity?2
04.03.Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now2
21.02.Roivant Sciences Ltd. - 8-K, Current Report12
10.02.Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position3
10.02.Roivant Sciences Ltd. - 10-Q, Quarterly Report-
10.02.Roivant Sciences reports Q3 results9
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1